This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: ARS Pharmaceuticals (SPRY), Gilead Sciences (GILD) and Icon (ICLR)

Tipranks - Tipranks - Fri Jun 26, 7:32AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ARS Pharmaceuticals (SPRY), Gilead Sciences (GILD) and Icon (ICLR) with bullish sentiments.

TipRanks' Prime Week Sale - 70% Off

ARS Pharmaceuticals (SPRY)

Cantor Fitzgerald analyst Joshua Schimmer maintained a Buy rating on ARS Pharmaceuticals yesterday and set a price target of $30.00. The company’s shares closed last Wednesday at $10.54.

According to TipRanks.com, Schimmer is a 5-star analyst with an average return of 19.0% and a 52.2% success rate. Schimmer covers the Healthcare sector, focusing on stocks such as Artiva Biotherapeutics, Inc., Mirum Pharmaceuticals, and CG Oncology, Inc. ;'>

ARS Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $28.33, a 172.1% upside from current levels. In a report released today, William Blair also maintained a Buy rating on the stock.

See today’s best-performing stocks on TipRanks >>

Gilead Sciences (GILD)

In a report released today, Louise Chen from Scotiabank maintained a Buy rating on Gilead Sciences, with a price target of $177.00. The company’s shares closed last Wednesday at $125.16.

According to TipRanks.com, Chen is a 4-star analyst with an average return of 3.8% and a 48.4% success rate. Chen covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Bristol-Myers Squibb, and Teva Pharmaceutical. ;'>

Currently, the analyst consensus on Gilead Sciences is a Strong Buy with an average price target of $160.37, which is a 27.7% upside from current levels. In a report issued on June 10, Citi also maintained a Buy rating on the stock with a $165.00 price target.

Icon (ICLR)

In a report released today, Sean Dodge from BMO Capital maintained a Buy rating on Icon, with a price target of $187.00. The company’s shares closed last Wednesday at $158.17.

According to TipRanks.com, Dodge ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -5.4% and a 42.1% success rate. Dodge covers the Healthcare sector, focusing on stocks such as BrightSpring Health Services, Inc., Aveanna Healthcare Holdings, and Lifestance Health Group. ;'>

Icon has an analyst consensus of Moderate Buy, with a price target consensus of $173.00, implying a 17.1% upside from current levels. In a report released today, RBC Capital also upgraded the stock to Buy with a $185.00 price target.

Read More on SPRY:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).